The Incidence of Prostate Cancer in Iran: Results of aPopulation-Based Cancer Registry

Author(s):

A. Sadjadi , M. Nooraie , A. Ghorbani , M. Alimohammadian , M. J. Zahedi , S. Darvish , Moghadam , H. Fakheri , M. Babai , S. Semnani , F. Mansour , Ghanaei , M. A. Mohagheghi

Message:
Abstract:
Background
Little is known about the epidemiology of prostate cancer in Iranian men. We carried out an active prostate cancer surveillance program in five provinces of Iran.
Methods
Data used in this study were obtained from population-based cancer registries between 1996 and 2000.
Results
The age-standardized incidence rate of prostate carcinoma in the five provinces was 5.1 per 100,000 person-years. No significant difference was seen in the age-standardized incidence rate of prostate cancer within the provinces studied. The mean±SD age of patients with prostate cancer was 67±13.5 years.
Conclusion
The incidence of prostate cancer in Iran is very low as compared to the Western countries. This can partly be explained by lack of nationwide screening program, younger age structure and quality of cancer registration system in Iran.
Language:
English
Published:
Archives of Iranian Medicine, Volume:10 Issue: 4, oct 2007
Page:
481
magiran.com/p593561  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
اطلاعات بیشتر
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!
More information